2024
Evaluation of F-537-Tetrazine in a model for brain pretargeting imaging. Comparison to N-(3-[18F] fluoro-5-(1,2,4,5-tetrazin-3-yl)benzyl)propan-1-amine
Shalgunov V, van den Broek S, Andersen I, Raval N, Schäfer G, Barz M, Herth M, Battisti U. Evaluation of F-537-Tetrazine in a model for brain pretargeting imaging. Comparison to N-(3-[18F] fluoro-5-(1,2,4,5-tetrazin-3-yl)benzyl)propan-1-amine. Nuclear Medicine And Biology 2024, 128: 108877. PMID: 38232579, DOI: 10.1016/j.nucmedbio.2024.108877.Peer-Reviewed Original Research
2023
Pretargeted imaging beyond the blood–brain barrier
Shalgunov V, van den Broek S, Andersen I, Vázquez R, Raval N, Palner M, Mori Y, Schäfer G, Herrmann B, Mikula H, Beschorner N, Nedergaard M, Syvänen S, Barz M, Knudsen G, Battisti U, Herth M. Pretargeted imaging beyond the blood–brain barrier. RSC Medicinal Chemistry 2023, 14: 444-453. PMID: 36970152, PMCID: PMC10034008, DOI: 10.1039/d2md00360k.Peer-Reviewed Original ResearchRational drug design approachDrug design approachBioorthogonal chemistryTetrazine ligationAttractive reactionPhysicochemical propertiesFluorine-18Blood-brain barrierLead compoundsMolecular imaging technologySoluble oligomersPositron emission tomographyBiomarker proteinsIdeal radionuclideTetrazineChemistryFavorable characteristicsDrug developmentOligomersPropertiesPretargetingNanomedicineCompoundsStructureReaction